Certara, Inc. (NASDAQ:CERT - Get Free Report) has been given an average rating of "Hold" by the thirteen analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $8.95.
Several brokerages have recently commented on CERT. Craig Hallum lowered their price objective on Certara from $10.00 to $8.00 and set a "hold" rating for the company in a research note on Tuesday, May 12th. KeyCorp lowered their target price on shares of Certara from $10.00 to $8.00 and set an "overweight" rating on the stock in a report on Monday, April 13th. Barclays upped their price target on shares of Certara from $6.50 to $7.50 and gave the stock an "equal weight" rating in a report on Wednesday. Robert W. Baird cut their target price on shares of Certara from $7.00 to $6.00 and set a "neutral" rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Certara in a report on Friday, May 29th.
Get Our Latest Stock Analysis on CERT
Certara Stock Up 2.7%
Shares of NASDAQ CERT opened at $8.01 on Thursday. The stock has a 50-day moving average price of $6.47 and a two-hundred day moving average price of $6.55. Certara has a 12 month low of $4.45 and a 12 month high of $13.88. The company has a current ratio of 2.55, a quick ratio of 1.88 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -17.80 and a beta of 1.44.
Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same period in the previous year, the firm earned $0.07 earnings per share. The company's revenue was down 10.8% compared to the same quarter last year. As a group, analysts forecast that Certara will post 0.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Certara during the 1st quarter valued at about $259,000. Goldman Sachs Group Inc. grew its stake in shares of Certara by 65.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock worth $2,267,000 after buying an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock valued at $2,965,000 after buying an additional 35,954 shares in the last quarter. Jane Street Group LLC boosted its holdings in Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock worth $2,743,000 after acquiring an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Certara by 29.3% in the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company's stock worth $1,089,000 after acquiring an additional 21,099 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.
About Certara
(
Get Free Report)
Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company's platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.
The company's offerings are divided into software tools and consulting services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
